[1] Wong MCS, Huang JLW, George J, et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol. 2019;16(1):57-73.

[2] Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151-171. 

[3] HE K，WANG X，ZENG Y，et al．A scientometric review of emerging trends and new developments in agricultural eclogical compensation．Environ SciPollut Res Int.2018, 5(17)： 6522-16532．

[4] Chen J, Zhang R, Li F, Lin S, Wang J. Integrated analysis and validation of TRIM23/p53 signaling pathway in hepatic stellate cells ferroptosis and liver fibrosis. Dig Liver Dis. 2023 Jul 24:S1590-8658(23)00764-8. 

[5] Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell. 2009;137(3):413-431. 

[6] Tian XF, Ji FJ, Zang HL, Cao H. Activation of the miR-34a/SIRT1/p53 Signaling Pathway Contributes to the Progress of Liver Fibrosis via Inducing Apoptosis in Hepatocytes but Not in HSCs. PLoS One. 2016 Jul 7;11(7):e0158657. 

[7] Sola S, Ma X, Castro RE, Kren BT, Steer CJ, Rodrigues CM. Ursodeoxycholic acid modulates E2F-1 and p53 expression through a caspase-independent mechanism in transforming growth factor beta1-induced apoptosis of rat hepatocytes. J Biol Chem. 2003;278(49):48831-48838.

[8] Song L, Chen TY, Zhao XJ, Xu Q, Jiao RQ, Li JM, Kong LD. Pterostilbene prevents hepatocyte epithelial-mesenchymal transition in fructose-induced liver fibrosis through suppressing miR-34a/Sirt1/p53 and TGF-β1/Smads signalling. Br J Pharmacol. 2019 Jun;176(11): 1619-1634.

[9] Yao L, Hu X, Yuan M, et al. IGF2-NR4A2 Signaling Regulates Macrophage Subtypes to Attenuate Liver Cirrhosis. J Clin Transl Hepatol. 2023;11(4):787-799. 

[10] Ren S, Chen J, Wang Q, et al. MicroRNA-744/transforming growth factor β1 relationship regulates liver cirrhosis. Hepatol Int. 2019;13(6):814-825.

[11] Ma L, Ma J, Ou HL. MicroRNA 219 overexpression serves a protective role during liver fibrosis by targeting tumor growth factor β receptor 2. Mol Med Rep. 2019;19(3): 1543-1550.

[12] Sak JJ, Prystupa A, Kiciński P, Luchowska-Kocot D, Kurys-Denis E, Bis-Wencel H. Leukocyte cell-derived chemotaxin-2 and fibroblast growth factor 21 in alcohol-induced liver cirrhosis. World J Hepatol. 2021;13(12): 2071-2080.

[13] Yu F, Dong P, Mao Y, et al. Loss of lncRNA-SNHG7 promotes the suppression of hepatic stellate cell activation via miR-378a-3p and DVL2
[J]. Molecular Therapy-Nucleic Acids, 2019, 17: 235-244.

[14] Kong Y, Huang T, Zhang H, et al. The lncRNA NEAT1/miR-29b/Atg9a axis regulates IGFBPrP1-induced autophagy and activation of mouse hepatic stellate cells
[J]. Life sciences, 2019, 237: 116902.

[15] Ye J, Lin Y, Yu Y, et al. LncRNA NEAT1/microRNA-129-5p/SOCS2 axis regulates liver fibrosis in alcoholic steatohepatitis
[J]. Journal of Translational Medicine, 2020, 18(1): 1-12.

[16] Wang Q, Wei S, Li L, et al. miR-139-5p sponged by LncRNA NEAT1 regulates liver fibrosis via targeting β-catenin/SOX9/TGF-β1 pathway
[J]. Cell Death Discovery, 2021, 7(1): 243.

[17] Su S B, Tao L, Liang X L, et al. Long noncoding RNA GAS5 inhibits LX-2 cells activation by suppressing NF-κB signalling through regulation of the miR-433–3p/TLR10 axis
[J]. Digestive and Liver Disease, 2022, 54(8): 1066-1075.

[18] Han M H, Lee J H, Kim G, et al. Expression of the long noncoding RNA GAS5 correlates with liver fibrosis in patients with nonalcoholic fatty liver disease
[J]. Genes, 2020, 11(5): 545.